World Journal of Dentistry

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  15 (2024)
Volume  14 (2023)
Volume  13 (2022)
Volume  12 (2021)
Volume  11 (2020)
Volume  10 (2019)
Volume  9 (2018)
Volume  8 (2017)
Volume  7 (2016)
Volume  6 (2015)
Volume  5 (2014)
Volume  4 (2013)
Volume  3 (2012)
Volume  2 (2011)
Volume  1 (2010)
Related articles

VOLUME 9 , ISSUE 2 ( March-April, 2018 ) > List of Articles

ORIGINAL RESEARCH

Association of Clinical Stages of Oral Submucous Fibrosis to Cytokeratin 19 Immunohistochemical Staining

BS Kiran Kumar, Shan N Malik, Zankana Vyas, Hemanth Kotari, Vishnudas D Prabhu

Keywords : Cytokeratin 19, Immunohistochemistry, Normal oral mucosa, Oral squamous cell carcinoma, Oral submucous fibrosis.

Citation Information : Kumar BK, Malik SN, Vyas Z, Kotari H, Prabhu VD. Association of Clinical Stages of Oral Submucous Fibrosis to Cytokeratin 19 Immunohistochemical Staining. World J Dent 2018; 9 (2):117-121.

DOI: 10.5005/jp-journals-10015-1519

License: CC BY-SA 4.0

Published Online: 01-10-2016

Copyright Statement:  Copyright © 2018; The Author(s).


Abstract

Introduction: Oral submucous fi brosis (OSF) i s t he m ost common potentially malignant disorders which is widely spread and has high malignant transformation rates. The use of immunohistochemical (IHC) studies has become one of the stepping stones to establish new surrogate markers to analyze the malignant transformation of a potentially malignant disorder to malignancy. Oral submucous fibrosis has been classified as stages 1, 2, and 3 according to severity of fibrosis and hyalinization, but the intensity of IHC staining of cytokeratin 19 (CK19) among these stages has not been done to analyze and establish the fact whether the intensity increases according to clinical stages. Materials and methods: Thirty-five cases of OSF were taken according to the clinical stages and an IHC study was done using CK19. The p-value was calculated using Fisher's exact tests. Results: Among 35 cases, 6 cases of stage 1 showed 33.3% of negative, 0% of mild, 50% of moderate, and 16.6% of intense staining. Twelve cases of stage 2 showed 16.6% of negative, 25% of mild, 33.3% of moderate, and 25% of intense staining. Seventeen cases of stage 3 showed 5.8% negative, 47% mild, 35.2% moderate, and 11.7% intense staining. The overall and comparative p-values were insignificant. Conclusion: Since the overall and comparative p-values were insignificant, the present study shows that there is no relation between the clinical stages of OSF and the CK19 staining. Hence, there is no increase in intensity according to clinical stages. Clinical significance: Establishing a direct relation between clinical stages of OSF and many cellular and extracellular proteins through IHC studies would make a well-established proof directly correlating the severity and staging in mouth opening to intensity of CK19. In this study, p-values were less and hence the study showed an insignificant clinical outcome.

PDF Share
  1. Prabhakaran SP, Muthukrishnan A. Expression of cytokeratin 18 and 19 in potentially malignant disorders: a systemic review. J Indian Acad Oral Med Radiol 2014 Oct;26(2):173-177.
  2. Nanda KD, Ranganathan K, Devi U, Joshua E. Increased expression of CK8 and CK18 in leukoplakia, oral submucous fibrosis, and oral squamous cell carcinoma: an immunohistochemistry study. Oral Surg Oral Med Oral Pathol Oral Radiol 2012 Feb;113(2):245-253.
  3. Kamath KP, Vidya M. Cytokeratin 19 expression patterns of dentigerous cysts and odontogenic keratocysts. Ann Med Health Sci Res 2015 Mar-Apr;5(2):119-123.
  4. Malik SN, Alam MK. Cytokeratin-14 expression in normal oral mucosal tissue, oral submucous fibrosis and oral squamous cell carcinoma: an immunohistochemical study. Int Med J 2014 May;21(2):223-225.
  5. Ranganathan K, Kavitha R, Sawant SS, Vaidya MM. Cytokeratin expression in oral submucous fibrosis – an immunohistochemical study. J Oral Pathol Med 2006 Jan;35(1):25-32.
  6. Wollina U, Verma SB, Ali FM, Patil M. Oral submucous fibrosis: an update. Clin Cosmet Invest Dermatol 2015 Apr;8(2): 193-204.
  7. Arakeri G, Rai KK, Hunasgi S, Maw M, Gao S, Brennan PA. Oral submucous fibrosis: an update on current theories of pathogenesis. J Oral Pathol Med 2017 Jul;46(6):406-412.
  8. Koneru A, Hunasgi S, Hallikeri K, Surekha R, Nellithady GS, Vanishree M. A systematic review of various treatment modalities for oral submucous fibrosis. J Adv Clin Res Insights 2014 Sep-Oct;2(1):64-72.
  9. Berwal V, Khangwal M, Solanki R, Khandeparker R, Savant K, Shetye O. Classification systems for oral submucous fibrosisfrom past to present: a review. Int J Dent Health Sci 2014;1(6): 900-913.
  10. Karemore TV, Karemore VA. Etiopathogenesis and treatment strategies of oral submucous fibrosis. J Indian Acad Oral Med Radiol 2011 Oct-Dec;23(4):598-602.
  11. Chourasia NR, Borle RM, Vastani A. Concomitant association of oral submucous fibrosis and oral squamous cell carcinoma and incidence of malignant transformation of oral submucous fibrosis in a population of central india: a retrospective study. J Maxillofac Oral Surg 2015 Dec;14(4):902-906.
  12. Prakash A, Grover N, Sengupta S, Singh S, Chaudhary S, Bharadwaj A. An immunohistochemical study of p53 expression in oral submucous fibrosis. Nepal Med Coll J 2015; 17(3-4):161-165.
  13. Nayak MT, Singh A, Desai RS, Vanaki SS. Immunohistochemical analysis of vimentin in oral submucous fibrosis. J Cancer Epidemiol 2013 May;2013:549041.
  14. Babiker AY, Rahmani AH, Abdalaziz MS, Albutti A, Aly SM, Ahmed HG. Expression analysis of p16 and cytokeratin 19 protein in the genesis of oral squamous cell carcinoma patients. Int J Clin Exp Med 2014 Jun;7(6):1524-1530.
  15. Lalli A, Tilakaratne WM, Ariyawardana A, Fitchett C, Leigh IM, Hagi-Pavli E, Cruchley AT, Parkinson EK, Teh MT, Fortune F, et al. An altered keratinocyte phenotype in oral sub mucous fibrosis; correlation of keratin K17 expression with disease severity. J Oral Pathol Med 2008 Apr;37(4):211-220.
  16. Tilakaratne WM, Iqbal Z, Teh MT, Ariyawardana A, Pitiyage G, Cruchley A, Stewart JE, Hagi-Pavli E, Lalli A, Waseem A, et al. Up regulation of HIF-1α in malignant transformation of oral sub mucous fibrosis. J Oral Pathol Med 2008 Jul;37(6): 372-377.
  17. Jack FW, Tagg JR, Ray B. Bacteriocins of gram positive bacteria. Microbiol Rev 1995 Jun;59(2):171-200.
  18. Du Plessis DJ, Nouwen N, Driessen AJ. The Sec translocase. Biochem Biophys Acta 2011 Mar;1808(3):851-865.
  19. Crandal AD, Montville T. Nisin resistance in Listeria monocytogenes ATCC 700302 is a complex phenotype. Appl Environ Microbiol 1998 Jan;64(1):231-237.
  20. Tong Z, Huang L, Ling J, Mao X, Ning Y, Deng D. Effects of intracanal irrigant MTAD combined with Nisin at sub- Minimum Inhibitory concentration levels on Enterococcus faecalis growth and the expression of pathogenic genes. PLoS One 2009 Mar;9(3):e90235.
  21. Tong Z, Zhang Y, Ling J, Ma J, Huang L, Zhang L. An in vitro study on the effects of nisin on the antibacterial activities of 18 antibiotics against Enterococcus faecalis. PLoS One 2014 Feb;9(2):e89209.
  22. Dametto FR, Ferraz CC, Gomes BP, Zaia AA, Teixeira FB, de Souza-Filho FJ. In vitro assessment of the immediate and prolonged antimicrobial action of chlorhexidine gel as an endodontic irrigant against Enterococcus faecalis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005 Jun;99(6):768-772.
  23. Bhandari S, Shivakumar AT, Patil CR. An in vitro evaluation of antimicrobial efficacy of 2% chlorhexidine gel, propolis and calcium hydroxide against Enterococcus faecalis in human root dentin. J Clin Diagn Res 2014 Nov;8(11):ZC60-ZC63.
  24. Gomes BP, Ferraz CC, Vianna ME, Rosalen PL, Zaia AA, Teixeira FB, Souza-Filho FJ. In vitro antimicrobial activity of calcium hydroxide pastes and their vehicles against selected microorganisms. Braz Dent J 2002;13(3):155-161.
  25. Madhubala MM, Srinivasan N, Ahamed S. Comparative evaluation of propolis and triantibiotic mixture as an intracanal medicament against Enterococcus faecalis. J Endod 2011 Sep;37(9):1287-1289.
  26. Kandaswamy D, Venkateshbabu N, Gogulnath D, Kindo AJ. Dentinal tubule disinfection with 2% chlorhexidine gel, propolis, morinda citrifolia juice, 2% povidone iodine and calcium hydroxide. Int Endod J 2010 May;43(5):419-423.
  27. Gandi P, Vasireddi SR, Gurram SR, Darasani K. Evaluation of antibacterial efficacy of omeprazole with sodium hypochlorite as an endodontic irrigating solution—an in vivo study. J Int Oral Health 2013 Apr;5(2):14-20.
  28. Saunders EM, Saunders WP. The heat generated on the external root surface during post space preparation. Int Endod J 1989 Jul;22(4):169-173.
  29. Eriksson JH, Sundström F. Temperature rise during root canal preparation—a possible cause of damage to tooth and periodontal tissue. Swed Dent J 1984;8(5):217-223.
  30. Mozini AC, Vansan LP, Sousa Neto MD, Pietro R. Influence of the length of remaining root canal filling and post space preparation on the coronal leakage of Enterococcus faecalis. Braz J Microbiol 2009 Jan;40(1):174-179.
  31. Oliver CM, Abbott PV. Correlation between clinical success and apical dye penetration. Int Endod J 2001 Dec;34(8): 637-644.
  32. Ioannou L, McClaren BJ, Massie J, Lewis S, Metcalfe SA, Forret L, Delatychi MB. Population-based carrier screening for cystic fibrosis: a systematic review of 23 years of research. Genet Med 2014 Mar;16(3):207-216.
  33. Premera. Noninvasive prenatal screening for fetal aneuploidies and microdeletions using cell-free DNA. Medical Policy No. 4.01.21, 2015. Available at: https://www.premera.com/ medicalpolicies/4.01.21.pdf
  34. Kohane IS, Masys DR, Altman RB. The incidentalome: a threat to genomic medicine. JAMA 2006 Jul;296(2):212-215.
  35. Committee on Ethics, American College of Obstetricians and Gynecologists; Committee on Genetics, American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 410: Ethical issues in genetic testing. Obstet Gynecol 2008 Jun; 111(6):1495-502.
  36. American Medical Association. Council on Ethical and Judicial Affairs. Code of medical ethics: current opinions with annotations / American Medical Association, Council on Ethical and Judicial Affairs; annotations prepared by the Southern Illinois University Schools of Medicine and Law, 2006-2007 ed. Chicago, Ill.: AMA Press, 2006. pp 399.
  37. Offit K, Groeger E, Turner S, Wadsworth EA, Weiser MA. The “duty to warn” a patient's family members about hereditary disease risks. JAMA 2004 Sep;292(12):1469-1473.
  38. Fluda KG, Lykens K. Ethical issues in predictive genetic testing: a public health perspective. J Med Ethics 2006 Mar:32(3):143-147.
  39. Committee on Ethics, American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 360: Sex selection. Obstet Gynecol 2007 Feb;109(2 Pt 1):475-478.
  40. Braude P. Preimplantation diagnosis for genetic susceptibility. N Engl J Med. 2006 Aug 10;355(6):541-543.
  41. Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, Wainscoat JS. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997 Aug 16;350(9076):485-487.
  42. Benn PA, Chapman AR. Ethical challenges in providing noninvasive prenatal diagnosis. 2010 Apr;22(2):128-134.
  43. Bianchi DW. At-home fetal DNA gender testing: caveat emptor. Obstet Gynecol 2006 Feb;107(2 Pt 1):216-218.
  44. Hall A, Bostanci A, John S. Ethical, legal and social issues arising from cell-free fetal DNA technologies. In: Appendix III to the report: Cell-free fetal nucleic acids for noninvasive prenatal diagnosis. Cambridge: PHG Foundation 2009. Available at: www.phgfoundation.org.
  45. Modell B. Delivering genetic screening to the community. Ann Med 1997 Dec;29(6):591-599.
  46. Peterlin B, Vidmar L, Borry P, et al. Expanded carrier screening tests currently on the commercial market. Eur J Hum Genet 2014; 22 (suppl 1):291.
  47. Kingsmore S. Comprehensive carrier screening and molecular diagnostic testing for recessive childhood diseases. PLoS Curr 2012 May:e4f9877ab8ffa9.
  48. World Health Organization. Identifying regional priorities in the area of human genetics in SEAR: Report of an intercountry consultation, Bangkok, Thailand, 23-25 September 2003. New Delhi: WHO Office for South East Asia Region; 2004. 26p.
  49. World Health Organization. Human Genomics in Global Health. Case Study: India. Geneva: WHO; 2006. Available at: http://www.who.int/genomics/policy/india/en/index7. html#content
  50. World Health Organization. The World Health Report 2005. Make every mother and child count. Geneva, Geneva: WHO; 2005. 219p.
  51. Ghosh, K, Mohanty D. Teaching of medical genetics in the medical colleges of India – way ahead. Ind J Med Genet 2002 Jul-Dec;8(2):43-44.
  52. Ganguly BB, Chakrabarti D. Urge of prenatal diagnosis in modernized civilization. Eur J Hum Genet 2009;17(Suppl. 2): 160.
  53. Dal Pizzol MM, Roggia MF, Kwitko S, Marinho DR, Rymer S. Use of fibrin glue in ocular surgery. Arq Bras Oftalmol 2009 May-Jun;72(3):308-312.
  54. Dintelmann T, Lieb WE, Grehn F. Filtering bleb revision. Techniques and outcome. Ophthalmologe 2002 Dec;99(12): 917-921.
  55. Du TT, Saffra N. Acellular dermal graft as a treatment of recurrent conjunctival wound dehiscence. Arch Ophthalmol 2009 Nov;127(11):1520-1521.
  56. Elmalem VI, Harris GJ. Occurrence and surgical management of a cerebrospinal fluid-filled cystoid space following routine enucleation. Ophthal Plast Reconstr Surg 2012 Sep-Oct;28(5):e117-e118.
  57. Esquenazi S, Rand W, Velazquez G, Grunstein L. Novel therapeutic approach in the management of band keratopathy using amniotic membrane transplantation with fibrin glue. Ophthalmic Surg Lasers Imaging 2008 Sep-Oct;39(5): 418-421.
  58. Freeman PD, Kahook MY, Curtis TH. Glaucoma drainage device implantation in children using fibrin glue. J AAPOS 2010 Apr;14(2):169-171.
  59. Piltz JR, Starita RJ. The use of subconjunctivally administered tissue plasminogen activator after trabeculectomy. Ophthalmic Surg 1994 Jan;25(1):51-53.
  60. Por YM, Tan YL, Mehta JS, Tan DT. Intracameral fibrin tissue sealant as an adjunct in tectonic lamellar keratoplasty for large corneal perforations. Cornea 2009 May;28(4):451-455.
  61. Sakarya Y, Sakarya R, Yildirim A. Sutureless amniotic membrane fixation with fibrin glue in symptomatic bullous keratopathy with poor visual potential. Eur J Ophthalmol 2010 Jan-Feb;20(1):249; author reply 249-250.
  62. Lee GA, Holcombe DJ. Surgical revision of dysfunctional filtration blebs with bleb preservation sliding conjunctival flap and fibrin glue. Eye (Lond) 2010 Jun;24(6):947-953.
  63. Kahook MY, Noecker RJ. Fibrin glue-assisted glaucoma drainage device surgery. Br J Ophthalmol 2006 Dec;90(12):1486-1489.
  64. Valimaki J. Fibrin glue for preventing immediate postoperative hypotony following glaucoma drainage implant surgery. Acta Ophthalmol Scand 2006 Jun;84(3):372-374.
  65. Malhotra C, Jain AK. Human amniotic membrane transplantation: different modalities of its use in ophthalmology. World J Transplant 2014 Jun;4(2):111-121.
  66. Dua HS, Gomes JA, King AJ, Maharajan VS. The amniotic membrane in ophthalmology. Surv Ophthalmol 2004 Jan-Feb;49(1):51-77.
  67. Shimmura S, Shimazaki J, Ohashi Y, Tsubota K. Antiinflammatory effects of amniotic membrane transplantation in ocular surface disorders. Cornea 2001 May;20(4):408-413.
  68. Yazdani S, Mahboobipour H, Pakravan M, Doozandeh A, Ghahari E. Adjunctive mitomycin c or amniotic membrane transplantation for Ahmed glaucoma valve implantation: a randomized clinical trial. J Glaucoma 2016 May;25(5):415-421.
  69. Sheha H, Kheirkhah A, Taha H. Amniotic membrane transplantation in trabeculectomy with mitomycin C for refractory glaucoma. J Glaucoma 2008 Jun-Jul;17(4):303-307.
  70. Khairy HA, Elsawy MF. Trabeculectomy with mitomycin-C versus trabeculectomy with amniotic membrane transplant: a medium-term randomized controlled trial. J Glaucoma 2015 Sep;24(7):556-559.
  71. Rauscher FM, Barton K, Budenz DL, Feuer WJ, Tseng SC. Long-term outcomes of amniotic membrane transplantation for repair of leaking glaucoma filtering blebs. Am J Ophthalmol 2007 Jun;143(6):1052-1054.
  72. Sethi P, Patel RN, Goldhardt R, Ayyala RS. Conjunctival advancement with subconjunctival amniotic membrane draping technique for leaking cystic blebs. J Glaucoma 2016 Feb;25(2):188-192.
  73. Kitagawa K, Yanagisawa S, Watanabe K, Yunoki T, Hayashi A, Okabe M, Nikaido T. A hyperdry amniotic membrane patch using a tissue adhesive for corneal perforations and bleb leaks. Am J Ophthalmol 2009 Sep;148(3):383-389.
  74. Nagai-Kusuhara A, Nakamura M, Fujioka M, Negi A. Longterm results of amniotic membrane transplantation-assisted bleb revision for leaking blebs. Graefes Arch Clin Exp Ophthalmol 2008 Apr;246(4):567-571.
  75. Rai P, Lauande-Pimentel R, Barton K. Amniotic membrane as an adjunct to donor sclera in the repair of exposed glaucoma drainage devices. Am J Ophthalmol 2005 Dec;140(6): 1148-1152.
  76. Ainsworth G, Rotchford A, Dua HS, King AJ. A novel use of amniotic membrane in the management of tube exposure following glaucoma tube shunt surgery. Br J Ophthalmol 2006 Apr;90(4):417-419.
  77. Papadaki TG, Siganos CS, Zacharopoulos IP, Panteleontidis V, Charissis SK. Human amniotic membrane transplantation for tube exposure after glaucoma drainage device implantation. J Glaucoma 2007 Jan;16(1):171-172.
  78. Mulder EJ, Leiblum DM, Visser GH. Fetal breathing movements in late diabetic pregnancy: relationship to fetal heart rate patterns and Braxton Hicks’ contractions. Early Hum Dev 1995 Nov;43(3):225-232.
  79. Schulte FJ, Michaelis R, Nolte R, Albert G, Parl U, Lasson U. Brain and behavioral maturation in newborn infants of diabetic mothers. I. Nerve conduction and EEG patterns. Neuropadiatrie 1969 Jan-Jul;1(1):24-35.
  80. Devoe LD, Youssef AA, Castillo RA, Croom CS. Fetal biophysical activities in third-trimester pregnancies complicated by diabetes mellitus. Am J Obstet Gynecol 1994 Aug;171(2):298-303.
  81. Dierker LJ Jr, Pillay S, Sorokin Y, Rosen MG. The change in fetal activity periods in diabetic and nondiabetic pregnancies. Am J Obstet Gynecol 1982 May;143(2):181-185.
  82. Doherty NN, Hepper PG. Habituation in fetuses of diabetic mothers. Early Hum Dev 2000 Aug;59(2):85-93.
  83. Kainer F, Prechtl HF, Engele H, Einspieler C. Assessment of the quality of general movements in fetuses and infants of women with type-1 diabetes mellitus. Early Hum Dev 1997 Nov;50(1):13-25.
  84. Mulder EJ, O'Brien MJ, Lems YL, Visser GH, Prechtl HF. Body and breathing movements in near-term fetuses and newborn infants of type-1 diabetic women. Early Hum Dev 1990 Nov;24(2):131-152.
  85. Mulder EJ, Visser GH. Growth and motor development in fetuses of women with type-1 diabetes. I. Early growth patterns. Early Hum Dev 1991 May;25(2):91-106.
  86. Mulder EJ, Visser GH. Growth and motor development in fetuses of women with type-1 diabetes. II. Emergence of specific movement patterns. Early Hum Dev 1991 May;25(2):107-115.
  87. Mulder EJ, Visser GH. Impact of early growth delay on subsequent fetal growth and functional development: a study on diabetic pregnancy. Early Hum Dev 1992 Dec;31(2):91-95.
  88. Mulder EJ, Visser GH, Bekedam DJ, Prechtl HF. Emergence of behavioral states in fetuses of type-1 diabetic women. Early Hum Dev 1987 Jul;15(4):231-251.
  89. Mulder EJ, Visser GH, Morssink LP, de Vries JI. Growth and motor development in fetuses of women with type-1 diabetes. III. First trimester quantity of fetal movement patterns. Early Hum Dev 1991 May;25(2):117-133.
  90. Aberg A, Westbom L, Kallen B. Congenital malformations among infants whose mothers had gestational diabetes or preexisting diabetes. Early Hum Dev 2001 Mar;61(2):85-95.
  91. Deregnier RA, Nelson CA, Thomas KM, Wewerka S, Georgieff MK. Neurophysiologic evaluation of auditory recognition memory in healthy newborn infants and infants of diabetic mothers. J Pediatr 2000 Dec;137(6):777-784.
  92. Nelson CA, Wewerka S, Thomas KM, Tribby-Walbridge S, deRegnier R, Georgieff M. Neurocognitive sequelae of infants of diabetic mothers. Behav Neurosci 2000 Oct;114(5):950-956.
  93. Reece EA, Homko CJ. Infant of the diabetic mother. Semin Perinatol 1994 Oct;18(5):459-469.
  94. Reece EA, Homko CJ. Why do diabetic women deliver malformed infants? Clin Obstet Gynecol 2000 Mar;43(1):32-45.
  95. Rizzo T, Metzger BE, Burns WJ, Burns K. Correlations between antepartum maternal metabolism and intelligence of offspring. N Engl J Med 1991 Sep;325(13):911-916.
  96. Rizzo TA, Metzger BE, Dooley SL, Cho NH. Early malnutrition and child neurobehavioral development: insights from the study of children of diabetic mothers. Child Dev 1997 Feb;68(1):26-38.
  97. Schwartz R, Teramo KA. Effects of diabetic pregnancy on the fetus and newborn. Semin Perinatol 2000 Apr;24(2):120-135.
  98. Vaarasmaki MS, Hartikainen A, Anttila M, Pramila S, Koivisto M. Factors predicting peri- and neonatal outcome in diabetic pregnancy. Early Hum Dev 2000 Jul;59(1):61-70.
  99. Robertson SS, Dierker LJ. Fetal cyclic motor activity in diabetic pregnancies: sensitivity to maternal blood glucose. Dev Psychobiol 2003 Jan;42(1):9-16.
  100. Accardo PJ, Blondis TA, Whitman BY. Disorders of attention and activity level in a referral population. Pediatrics 1990 Mar;85(3 Pt 2):426-431.
  101. Ornoy A, Uriel L, Tennenbaum A. Inattention, hyperactivity and speech delay at 2-4 years of age as a predictor for ADDADHD syndrome. Isr J Psychiatry Relat Sci 1993;30(3):155-163.
  102. Smyth TR. Impaired motor skill (clumsiness) in otherwise normal children: a review. Child Care Health Dev 1992 Sep-Oct;18(5):283-300.
  103. Petersen MB, Pedersen SA, Greisen G, Pedersen JF, Mølsted- Pedersen L. Early growth delay in diabetic pregnancy: relation to psychomotor development at age 4. Br Med J (Clin Res Ed) 1988 Feb;296(6622):598-600.
  104. Sells CJ, Robinson NM, Brown Z, Knopp RH. Long-term developmental follow-up of infants of diabetic mothers. J Pediatr 1994 Jul;125(1):S9-S17.
  105. Vladareanu R, Lebit D, Constantinescu S. Ultrasound assessment of fetal neurobehaviour in high risk pregnancies. DSJUOG 2012 Apr-Jun;6(2):132-147.
  106. Talic A, Kurjak A, Ahmed B, Stanojevic M, Predojevic M, Kadic AS, Di Renzo GC. The potential of 4D sonography in the assessment of fetal behavior in high-risk pregnancies. J Matern Fetal Neonatal Med 2011 Jul;24(7):948-954.
  107. Bekedam DJ, Visser GH, de Vries JJ, Prechtl HF. Motor behaviour in the growth retarded fetus. Early Hum Dev 1985 Nov;12(2):155-165.
  108. Cioni G, Prechtl HF. Preterm and early postterm motor behaviour in low-risk premature infants. Early Hum Dev 1990 Sep;23(3):159-191.
  109. Seme-Ciglenecki P. Predictive value of assessment of general movements for neurological development of highrisk preterm infants: comparative study. Croat Med J 2003 Dec;44(6):721-727.
  110. Abo-Yaqoub S, Kurjak A, Mohammed AB, Shadad A, Abdel-Maaboud M. The role of 4-D ultrasonography in prenatal assessment of fetal neurobehaviour and prediction of neurological outcome. J Matern Fetal Neonatal Med 2012 Mar;25(3):231-236.
  111. Athanasiadis AP, Mikos T, Tambakoudis GP, Theodoridis TD, Papastergiou M, Assimakopoulos E, Tarlatzis BC. Neurodevelopmental fetal assessment using KANET scoring system in low and high-risk pregnancies. J Matern Fetal Neonatal Med 2013 Mar;26(4):363-368.
  112. Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012 Jan;97(1):28-38.e25
  113. Sirmans SM, Pate KA. Epidemiology, diagnosis and management of polycystic ovary syndrome. Clin Epidemiol 2014; 6:1-13.
  114. Fauser BC, Diedrich K, Bouchard P, Domínguez F, Matzuk M, Franks S, Hamamah S, Simón C, Devroey P, Ezcurra D, et al. Contemporary genetic technologies and female reproduction. Human Reproduction Update 2011 Nov;17(6):829-847.
  115. Balen A, Conway G, Kaltsas G. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod 1995 Aug;10(8):2107-2111.
  116. Azziz R, Sanchez L, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, Taylor K, Boots LR. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 2004 Feb;89(2):453-462.
  117. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at longterm follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000 May;52(5):595-600.
  118. Hollinrake E, Abreu A, Maifeld M, Van Voorhis BJ, Dokras A. Increased risk of depressive disorders in women with polycystic ovary syndrome. Fertil Steril 2007 Jun;87(6): 1369-1376.
  119. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome. In: Givens JHF, Merriman G, editors. The polycystic ovary syndrome. Cambridge, MA: Blackwell Scientific; 1992. p. 377-384.
  120. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004 Jan;81(1):19-25.
  121. Azziz R, Carmina E, DeWailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006 Nov;91(11):4237-4245.
  122. Lujan ME, Jarrett BY, Brooks ED, Reines JK, Peppin AK, Muhn N, Haider E, Pierson RA, Chizen DR. Updated ultrasound criteria for polycystic ovary syndrome: reliable thresholds for elevated follicle population and ovarian volume. Hum Reprod 2013 May;28(5):1361-1368.
  123. Badawy A, Elnashar A. Treatment options for polycystic ovary syndrome. Int J Womens Health 2011 Feb;3:25-35.
  124. ACOG Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin No 108: Polycystic ovary syndrome. Obstet Gynecol 2009 Oct;114(4):936-949.
  125. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 2008 Mar;89(3): 505-522.
  126. Balen AH. Ovulation induction in the management of anovulatory polycystic ovary syndrome. Mol Cell Endocrinol 2013 Jul;373(1-2):77-82.
  127. Berridge DL, Winter TC. Saline infusion sonohysterography: technique, indications, and imaging findings. J Ultrasound Med 2004 Jan;23(1):97-112.
  128. Allison SJ, Horrow MM, Kim HY, Lev-Toaff AS. Salineinfused sonohysterography: tips for achieving greater success. Radiographics 2011 Nov-Dec;31(7):1991-2004.
  129. O'Neill MJ. Sonohysterography. Radiol Clin North Am 2003 Jul;41(4):781-797.
  130. Bonnamy L, Marret H, Perrotin F, Body G, Berger C, Lansac J. Sonohysterography: a prospective survey of results and complications in 81 patients. Eur J Obstet Gynecol Reprod Biol 2002 Apr;102(1):42-47.
  131. Lindheim SR, Adsuar N, Kushner DM, Pritts EA, Olive DL. Sonohysterography: a valuable tool in evaluating the female pelvis. Obstet Gynecol Surv 2003 Nov;58(11):770-784.
  132. Lindheim SR, Sprague C, Winter TC. Hysterosalpingography and sonohysterography: lessons in technique. AJR Am J Roentgenol 2006 Jan;186(1):24-29.
  133. Jeanty P, Besnard S, Arnold A, Turner C, Crum P. Air-contrast sonohysterography as a first step assessment of tubal patency. J Ultrasound Med 2000 Aug;19(8):519-527.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.